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Abstract
Background: Treatment of multi-drug-resistant strains of pneumonia with common antibiotics in renal patients is ineffective and
physicians are compelled to use Colistin for such cases.
Objectives: This study was conducted to assess the mortality, length of stay, and renal damages in the treatment of multi-drug-
resistant pneumonia with Colistin among multiple trauma patients admitted to the emergency department and transferred to the
ICU.
Methods: This retrospective cohort study was conducted between 2011 and 2016. 102 multiple trauma (MT) patients with multi-
drug-resistant strains of hospital-acquired pneumonia (HAP) admitted to the emergency department then transferred to the ICU
were assessed. All patients received Colistin according to their weight. Renal damage was evaluated according to the RIFLE criteria.
The mortality and the length of stay were assessed. In order to statistically analyze the data, SPSS version 23 software was used to
conduct t-test and chi-square test.
Results: Out of 102 patients, 55 (54%) died and 50 (49.1%) developed acute renal failure; 64 cases had no hypertension. Patients
according to the RIFLE index were assessed: Risk (11.01%), Injury (14%), Failure (18%), Loss (6%), and End-stage renal disease. The preva-
lence and prognosis of acute kidney injury in multiple trauma patients treated with Colistin were significantly correlated with drug
dosage, body mass index, and use of corticosteroids (when assessed using relevant scoring systems, P < 0.05).
Conclusions: The use of a scoring system in the intensive care unit, determining those patients requiring Colistin, and adjusting
the dosage of this drug for treatment of MT patients with multi-drug resistant strains of HAP are vital. Creatinine levels must be
carefully monitored.
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1. Background
Development of resistance to common antibiotics has
particular importance in the hospital settings to prevent
treatment failure (1-5). Nowadays, many types of hospital-
acquired pneumonia (HAP) do not respond to common an-
tibiotics and lead to morbidity and mortality (6-10). Pneu-
monia is the second common cause of hospital infection
and comprises about 15% of all cases (11-14). Its highest
prevalence is in the intensive care unit (1, 15-18). Multi-drug-
resistant strains are one of the factors that create problems
when treating HAP infections (19-22). Antibiotic resistance
in HAP is an indication of administration of Colistin (23-
25).
Colistin or Polymyxin B exerts its antibacterial effects
by destroying the cell membrane of bacteria and increas-
ing permeability, resulting in cell death (26-29). Colistin
has high bactericidal effects on many strains that are re-
sistant to different types of antibiotics (30-33). Its effect on
pneumonia and Acinetobacter has been proven (34-36).
One report mentions that treating HAP with Colistin
had only a 25% positive response, due to its low penetration
in lung tissues (37). On the other hand, using high dosages
has severe side effects such as renal and neurotoxic dam-
ages (38, 39). Chen and colleagues (2015) found no signif-
icant difference between mono-therapy with Colistin and
a multi-drug regimen containing Colistin plus another an-
tibiotic. They compared treatment regimens and assessed
mortality, hospitalization duration, and prevalence of re-
nal damage (40).
Koksal and colleagues (2016) investigated incidence
and risk factors for renal damage caused by Colistin. Fac-
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tors associated with renal damage were old age, high lev-
els of Creatinine, diabetes, and chronic obstructive pul-
monary disease (41). Binh and colleagues (2015) reported
a 67.9% success rate when treating patients with Colistin.
However, 21.4% of the patients experienced renal dam-
age (42). Elefritz and colleagues showed that increasing
the dosage of Colistin did not increase the treatment suc-
cess rate. They also reported no renal damage caused by
increased dosages. However, large-scale studies are still
needed (43). Valachis and colleagues (2015) investigated
the effectiveness of Colistin spray in treating pneumonia.
They stated that it increases the effectiveness of treatment.
These studies did not report any increase in renal damage
of Colistin spray (44).
2. Objectives
This study was conducted to assess hospital outcomes
of treatment of multi-drug resistant HAP using Colistin
in patients admitted to the emergency department and
transferred to ICU.
3. Methods
The current study was retrospective cohorts from 2011
to 2016. 102 patients with HAP with multi-drug resistance
at our hospital treated with Colistin entered the study.
These patients admitted to the emergency department and
then transferred to ICU.
Acute kidney injury (AKI), formerly called acute renal
failure (ARF), was assessed using RIFLE classification. RIFLE
is an acronym for Risk, Injury, Failure, Loss, and End-stage
kidney disease.
Hospitalized patients with multi-drug-resistant strains
of HAP that were treated by Colistin were assessed. Patients
with a history of the renal disorder or renal failure, dialysis
patients, individuals with a history of Colistin sensitivity,
pregnant women, and patients with incomplete records
were excluded.
Data on gender, age, body mass index, history of dia-
betes, hypertension, Creatinine level upon admission and
at the beginning of treatment, daily dose of Colistin, du-
ration of use, septic shock, APACHE- II, and sequential or-
gan failure assessment scores (SOFA) were recorded. Quan-
titative variables and standard deviation (mean± SD) and
qualitative data percentages were assessed.
To analyze quantitative and qualitative data, the t-test
and chi-square test were used, respectively. Data were ana-
lyzed by SPSS version 23.
4. Results
The findings of the current study showed that among
102 patients, 64 were men and 38 were women with CPIS
scores of 6 or higher and without dialysis. The highest and
the lowest frequencies were in 2015 (43 patients, 42.1%) and
2012 (7 patients, 6.8%), respectively. The highest frequency
was in the 50-year-old age group and the lowest was in the
below 30-year-old age group; 64 cases (62%) did not have
hypertension; 78 patients (76%) did not have diabetes; 55
cases (56.1%) were moribund. Patients had different lev-
els of Colistin. Administration of 3 million units of Col-
istin had the highest frequency among the different doses
administered. The findings also showed that most of the
patients (80 cases) were administered with other antibi-
otics along with Colistin. Patients were categorized into 3
groups in terms of Creatinine level before giving Colistin.
The group exhibiting Creatinine level less than 1 had the
highest frequency (57.9%). In terms of Creatinine level at
discharge from the ICU, the patients were categorized into
3 groups. The group with Creatinine level of more than 11.5
had the highest frequency (70.7%). Most of the patients (70)
had a septic shock.
RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney
disease) is a popular ranking system; it categorizes pa-
tients with renal failure into 5 groups based on glomeru-
lar filtration and urine production. The current study in-
vestigated renal damage based on the RIFLE classification.
Based on the findings, 50 patients (49.01%) had a chronic re-
nal failure. Their RIFLE classification was calculated as fol-
lows: risk (11.01%), injury (14%), failure (18%), loss (6%), and
end-stage renal disease.
Diabetes showed a significant impact on renal failure,
hospital mortality, and hospitalization duration (P < 0.05).
Creatinine level before Colistin administration had a sig-
nificant impact on the prevalence of renal failure, hos-
pital mortality, and hospitalization duration (P < 0.05).
APACHE-II score had a significant impact on the prevalence
of renal failure, hospital mortality, and hospitalization du-
ration (P < 0.05). The increasing APACHE-II score increased
the mentioned outcomes. Based on the findings, SOFA
score also had a significant impact on renal damage, hos-
pital mortality, and hospitalization duration (P < 0.05), so
that increasing the SOFA score resulted in an increase in
the mentioned outcomes.
5. Discussion
Using a scoring system for disease severity may be a
guide for the medical staff to evaluate patient’s outcomes
or estimate the chance for improvement (45). These prog-
noses may be useful in estimating patient’s physiologic in-
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Table 1. Demographic Information of Patients
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stability upon admission (46). In addition, severity scor-
ing and forecasting mortality for each patient can be per-
formed along with clinical assessment in the ICU in order
to increase chances of survival (47, 48).
Based on the findings of the current study, there was
a positive significant association between APACHE-II score,
renal damage, mortality, and ICU duration. Several stud-
ies have investigated the association between these crite-
ria and outcomes in patients with different diseases, find-
ing a significant association. Asadizandi and colleagues in
a study, which estimated mortality using APACHE-II sever-
ity scoring system in patients hospitalized in the ICU, cal-
culated the APACHE-II score for both surviving and dead
patients as 13.16 and 17.15, respectively. The association was
statistically significant. The mortality rate in patients with
scores less than 15 was estimated to be 15%; for patients
with scores from 16 to 19, it was estimated to be 36%, and
finally, in patients with a score from 13 to 20, it was 100%
(49). Rahimzadeh and colleagues in a study showed that
this scoring system could predict mortality in ICU patients
(50). These results were also similar to the findings of De
Campos et al. (51) and Costa e Silva et al. (52). The reason for
consistency of the results of the current study with those
of other studies can be the applicability of APACHE-II crite-
rion in different diseases, particularly in renal diseases. Us-
ing this criterion during the first days of hospitalization in
the ICU can predict outcomes with a high probability and
provide a useful guide for healthcare teams in providing a
more efficient care.
Therefore, different outcome-predicting systems, such
as APACHE, SAPS, and SOFA, are used to forecast the final
outcomes of ICU patients. Using a forecasting system such
as APACHE-II can lead to the prediction of patient’s long-
term or short-term hospitalization. Mortality among pa-
tients with chronic renal damage also can be predicted.
Calculating the SOFA score in determining mortality
and prognosis in chronic renal damage was another find-
ing of the current study. An increase in the SOFA score re-
sulted in more severe consequences and outcomes. SOFA
is a common and valid criterion in scoring disease severity.
Few studies used this criterion in Iran and enough atten-
tion has not been paid to it. Based on the findings of Hos-
seini and Ramazani, the SOFA scoring system has a good
precision in forecasting outcomes in the surgical ICU as
well as in the internal ICU (53). It seems that in different
hospital contexts and types of antibiotic resistance, differ-
ent scoring models should be used to evaluate patients in
ICU and using these models is not recommended in all set-
tings. Evaluation of the primary situation using these sys-
tems should be determined.
The association between Colistin dose and prognosis
of patients with chronic renal damage was another find-
ing of our current study. Based on the findings of the cur-
rent study, Colistin dose had a significant impact on renal
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Table 2. Analytical Table for Some Main Variables Such as Creatinine Before Colistin, Underlying Diseases, APACHE, and SOFA
Variables Groups Acute Renal Failure Mortality Length of Stay, Days
Yes (N = 50) No (N = 52) Yes (N = 55) No (N = 47)
Diabetes mellitus
Yes (N = 24) 16 8 13 11 37.67
No (N = 78) 34 44 42 36 39.01
Statistical analysis Chi score = 16.96, P = 0.04 Chi score = 13.1, P = 0.04 T test = 8.92, P = 0.00
APACHE-II
0 - 15 (N = 16) 4 12 5 11 35.42
16 - 19 (N = 36) 8 28 12 24 38.55
20 - 30 (n = 39) 28 11 30 9 38.97
30 > (N = 11) 10 1 8 3 40.41
Statistical analysis Chi score = 14.07, P = 0.03 Chi score = 16.69, P = 0.02 T test = 6.4, P = 0.04
Sofa
< 5 (N = 12) 2 10 3 9 37.3
5 - 10 (N = 18) 6 12 11 7 37.84
11 - 15 (N = 58) 32 26 37 21 38.7
15 > (N = 14) 10 4 4 10 39.81
Statistical analysis Chi score = 19.76, P = 0.00 Chi score = 21.2, P = 0.01 T test = 8.2, P = 0.00
Creatinine before Colistin
< 1 (N = 59) 22 37 27 32 38.5
1 - 1.5 (N = 40) 29 11 25 15 38.69
1.5 > (N = 3) 3 0 3 0 39.31
Statistical analysis Chi score = 22.24, P = 0.00 Chi score = 22.7, P = 0.00 T test = 9.42, P = 0.00
damage and mortality (P < 0.05); but there was no signifi-
cant association between dosage and hospitalization dura-
tion. Since Colistin dosage is based on the Creatinine level
(i.e. with an increase in Creatinine level the dose of Col-
istin reduced and vice-versa), determining the impact of
the dosage in chronic renal damage, mortality, and hospi-
talization duration is critical. The association between un-
derlying diseases and renal chronic damages is another is-
sue that has been investigated in different studies. Based
on the findings of the current study, diabetes is directly as-
sociated with renal damage and mortality. This has been
investigated in other studies. Gul and colleagues (54) and
Rocco and colleagues (55) found a significant association
between diabetes and renal damages in patients using Col-
istin; this is not consistent with the results of the cur-
rent study. In the current study, 23% of the patients with
chronic renal damage were diabetics, and in patients with
no renal damage, it was 21%; no significant association was
found. Considering the underlying diseases such as dia-
betes, the association with chronic renal damage may vary
by lifestyle factors such as a history of nutritional regime
or smoking.
5.1. Conclusion
Based on the findings of the current study, the preva-
lence and prognosis of chronic renal damages have a di-
rect significant association with the type of scoring system,
drug dosage, body mass index, and septic shock. These sys-
tems may be useful in prioritizing patients requiring more
care. Taking the scores of these systems into account may
reduce renal damage associated with Colistin use in HAP
patients.
5.2. Limitations
This study was conducted only in one hospital in
Tehran city, Iran. Therefore, the findings need to be inter-
preted and generalized by caution. More research in this
area is needed before generalizing the study findings.
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